OTCBB ALERTS

[Mandroid]

CSMG Technologies, Inc.(OTCBB:CTUM) announced today that Dr. Anatoly Makarov, holder of Thoracic
Surgery and pulmonology chair at Kiev Medical Academy for Postgraduate Studies,
has successfully completed breakthrough lung resection procedures using the
company's platform live biological tissue welding/bonding technology.

CSMG owns the technology and exclusive world rights to the medical device
through Live Tissue Connect, Inc. (LTC), a subsidiary corporation formed for the
development and exploitation of the platform technology.

Makarov said, "Using the tissue welding technology for lung resection is faster,
results in less bleeding and does not require staples, sutures, glues or
sealant. There is higher reliability for a leak-proof seal than competitors and
has almost no probability of infection. Out of 400 surgeries at my clinic using
the tissue welding technology, I cannot recall one incidence of infection."

Donald S. Robbins, president and CEO of CSMG, said, "The big advantage of this
breakthrough is a shortened surgery time and that no foreign matter is left in
the lung. The surgery leaves the healthy lung lobe portion functional in the
body while removing the diseased lung lobe tissue."

The tissue welding/bonding technology for repair and reconnection of tissue and
hollow organs is smokeless, with little heat migration in the tissue, results in
no necrosis and is without the use of foreign matter or conventional
wound-closing devices, such as of staples, sutures, glues or sealant. The
procedures are almost bloodless. Unlike other tissue coagulation methods that
tend to destroy tissue by charring, searing and necrosis, the CSMG-patented
technology bonds and reconnects incised tissue using a patented low-heat
delivery method aimed at restoring the normal functions of the live organs and
tissue. The technology leaves little or no scar visible to the naked eye.

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 10 Ukraine hospitals and clinics are using the tissue
welding/bonding technology in clinical trials, have completed more than 5,000
human surgeries using almost 70 types of open and laparoscopic surgical
procedures and demonstrated that the technology is universal in its ability to
repair soft biological tissue. These surgeries included lung, neuro-surgery,
nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood
vessels, nerves, alba linea, uterus, bladder, gynecology, fallopian tube, ovary
and testicles, dura-matter, with little or no scarring, while restoring the
normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O.
Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at
Kiev, Ukraine, headed by Professor B.E. Paton. United States and Australia
patents have been issued with other U.S. and foreign patents pending.

About CSMG Technologies

CSMG Technologies maintains offices in Corpus Christi, Texas; Washington D.C.;
Atlanta, Ga.; and Kiev, Ukraine. For CSMG's stock quotes, visit
http://www.otcbb.com. For more information, visit http://www.ctum.com, e-mail
[e-mail], or contact Don Robbins at [phone].

Additional information about CSMG can be found at http://www.ctum.com or e-mail
[e-mail]. An online investor kit containing CSMG press releases,
SEC filings, current Level II price quotes, interactive Java, stock charts and
other useful information for investors can be found at
http://www.hawkassociates.com/csmg and
http://www.hawkassociates.com/csmg/kit.htm.

Investors may contact Don Robbins or K. Bruce Jones, CSMG, at [phone],
e-mail: [e-mail], or Frank Hawkins or Julie Marshall, Hawk
Associates, at [phone], e-mail: [e-mail].

Safe-Harbor Statement under the Private Securities Litigation Reform Act of
1995: This press release may contain forward-looking information within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the
Exchange Act), including all statements that are not statements of historical
fact regarding the intent, belief or current expectations of the company, its
directors or its officers with respect to, among other things: (i) the company's
financing plans; (ii) trends affecting the company's financial condition or
results of operations; (iii) the company's growth strategy and operating
strategy; and (iv) the declaration and payment of dividends. The words "may,"
"would," "will," "expect," "estimate," "anticipate," "believe," "intend" and
similar expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, many of which are beyond the company's ability to
control, and that actual results may differ materially from those projected in
the forward-looking statements as a result of various factors.

CONTACT: CSMG Technologies, Inc.
Donald S. Robbins, President and CEO
361-887-7546
K. Bruce Jones
770-955-0409